Advanced search
Publication Cover
Clinical Toxicology Volume 48, 2010 - Issue 3
Submit an article Journal homepage
1,380
Views
40
CrossRef citations to date
0
Altmetric
Case Reports

Multiorgan failure from 1-benzylpiperazine ingestion – legal high or lethal high?

Paul Gee Department of Emergency Medicine, Christchurch Hospital, Christchurch, New ZealandCorrespondence[email protected]
,
Tom Jerram Emergency Department, Christchurch Hospital, Christchurch, New Zealand
&
David Bowie ICU, Christchurch Hospital, Christchurch, New Zealand
Pages 230-233 | Received 21 Jul 2009, Accepted 31 Aug 2009, Published online: 25 Feb 2010

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Simon L. Hill & Simon H. L. Thomas. (2011) Clinical toxicology of newer recreational drugs. Clinical Toxicology 49:8, pages 705-719.
Read now
Leo J. Schep, Robin J. Slaughter, J. Allister Vale, D. Michael G. Beasley & Paul Gee. (2011) The clinical toxicology of the designer “party pills” benzylpiperazine and trifluoromethylphenylpiperazine. Clinical Toxicology 49:3, pages 131-141.
Read now
JR Kerr & LS Davis. (2011) Benzylpiperazine in New Zealand: brief history and current implications. Journal of the Royal Society of New Zealand 41:1, pages 155-164.
Read now

Articles from other publishers (37)

Ana Y. Simão, Mónica Antunes, Emanuel Cabral, Patrik Oliveira, Luana M. Rosendo, Ana Teresa Brinca, Estefânia Alves, Hernâni Marques, Tiago Rosado, Luís A. Passarinha, Maristela Andraus, Mário Barroso & Eugenia Gallardo. (2022) An Update on the Implications of New Psychoactive Substances in Public Health. International Journal of Environmental Research and Public Health 19:8, pages 4869.
Crossref
Paul Gee & Leo J. Schep. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances 301 332 .
Deborah Rudin, Matthias E. Liechti & Dino Luethi. (2021) Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. Experimental Neurology 343, pages 113778.
Crossref
Dino Luethi & Matthias E. Liechti. (2020) Designer drugs: mechanism of action and adverse effects. Archives of Toxicology 94:4, pages 1085-1133.
Crossref
Caroline Souto, Gabriela Göethel, Caroline Portela Peruzzi, Larissa Vivan Cestonaro, Ingrid Garcia, Daiana Silva Ávila, Vera Eifler‐Lima, Helena Carmo, Maria de Lurdes Bastos, Solange C. Garcia & Marcelo Dutra Arbo. (2019) Piperazine designer drugs elicit toxicity in the alternative in vivo model Caenorhabditis elegans . Journal of Applied Toxicology 40:3, pages 363-372.
Crossref
Michael D. Coleman. 2020. Human Drug Metabolism. Human Drug Metabolism 571 625 .
M. Rosaria Varì, Simona Pichini, Raffaele Giorgetti & Francesco P. Busardò. (2018) New psychoactive substances—Synthetic stimulants. WIREs Forensic Science 1:2.
Crossref
J. Neugarten, B. Friedman & L. Golestaneh. 2018. Comprehensive Toxicology. Comprehensive Toxicology 304 339 .
Andrew King, Mirjana Dimovska & Luke Bisoski. (2018) Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension. Current Hypertension Reports 20:1.
Crossref
Thomas GeschwindeThomas Geschwinde. 2018. Rauschdrogen. Rauschdrogen 1 392 .
L. J. Schep, H. A. Poulsen & P. Gee. 2017. Detection of Drug Misuse: Biomarkers, Analytical Advances and Interpretation. Detection of Drug Misuse: Biomarkers, Analytical Advances and Interpretation 100 124 .
Marcelo Dutra Arbo, Simone Melega, Regina Stöber, Markus Schug, Eugen Rempel, Jörg Rahnenführer, Patricio Godoy, Raymond Reif, Cristina Cadenas, Maria de Lourdes Bastos, Helena Carmo & Jan G. Hengstler. (2016) Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis. Archives of Toxicology 90:12, pages 3045-3060.
Crossref
Karolina Persona, Anna Polus, Joanna Góralska, Anna Gruca, Aldona Dembińska-Kieć & Wojciech Piekoszewski. (2016) An In Vitro Study of the Neurotoxic Effects of N-Benzylpiperazine: A Designer Drug of Abuse. Neurotoxicity Research 29:4, pages 558-568.
Crossref
Julia Dinger, Markus R. Meyer & Hans H. Maurer. (2014) In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Archives of Toxicology 90:2, pages 305-318.
Crossref
M. D. Arbo, R. Silva, D. J. Barbosa, D. Dias da Silva, S. P. Silva, J. P. Teixeira, M. L. Bastos & H. Carmo. (2016) In vitro neurotoxicity evaluation of piperazine designer drugs in differentiated human neuroblastoma SH-SY5Y cells . Journal of Applied Toxicology 36:1, pages 121-130.
Crossref
Steven Karch & Olaf Drummer. 2015. Karch's Pathology of Drug Abuse, Fifth Edition. Karch's Pathology of Drug Abuse, Fifth Edition 273 364 .
Markus R. Meyer, Anna Holderbaum, Pierce Kavanagh & Hans H. Maurer. (2015) Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP). Journal of Mass Spectrometry 50:10, pages 1163-1174.
Crossref
Brenda Wasunna, Emily Thomas & Sally Morgan. (2015) Development of legal highs. Journal of Psychiatric Intensive Care 11:02, pages 128-137.
Crossref
D. Dias-da-Silva, M.D. Arbo, M.J. Valente, M.L. Bastos & H. Carmo. (2015) Hepatotoxicity of piperazine designer drugs: Comparison of different in vitro models. Toxicology in Vitro 29:5, pages 987-996.
Crossref
Brian P. Kersten & Megan E. McLaughlin. (2014) Toxicology and Management of Novel Psychoactive Drugs. Journal of Pharmacy Practice 28:1, pages 50-65.
Crossref
Nicola M. Beckett, Sarah L. Cresswell, Darren I. Grice & James F. Carter. (2015) Isotopic profiling of seized benzylpiperazine and trifluoromethylphenylpiperazine tablets using δ13C and δ15N stable isotopes. Science & Justice 55:1, pages 51-56.
Crossref
Marcelo Dutra Arbo, Renata Silva, Daniel José Barbosa, Diana Dias da Silva, Luciana Grazziotin Rossato, Maria de Lourdes Bastos & Helena Carmo. (2014) Piperazine designer drugs induce toxicity in cardiomyoblast h9c2 cells through mitochondrial impairment. Toxicology Letters 229:1, pages 178-189.
Crossref
Randy L. Luciano & Mark A. Perazella. (2014) Nephrotoxic effects of designer drugs: synthetic is not better!. Nature Reviews Nephrology 10:6, pages 314-324.
Crossref
Michael E. Nelson, Sean M. Bryant & Steven E. Aks. (2014) Emerging drugs of abuse. Disease-a-Month 60:3, pages 110-132.
Crossref
Michael E. Nelson, Sean M. Bryant & Steven E. Aks. (2014) Emerging Drugs of Abuse. Emergency Medicine Clinics of North America 32:1, pages 1-28.
Crossref
Raimondo Bruno, Rosalie Poesiat & Allison Jane Matthews. (2013) Monitoring the Internet for emerging psychoactive substances available to Australia. Drug and Alcohol Review, pages n/a-n/a.
Crossref
Márcia Sá Monteiro, Maria de Lourdes Bastos, Paula Guedes de Pinho & Márcia Carvalho. (2013) Update on 1-benzylpiperazine (BZP) party pills. Archives of Toxicology 87:6, pages 929-947.
Crossref
Paul Gee & Leo Schep. 2013. Novel Psychoactive Substances. Novel Psychoactive Substances 179 209 .
Camilla Montesano, Manuel Sergi, Mariaelena Moro, Sabino Napoletano, Francesco Saverio Romolo, Michele Del Carlo, Dario Compagnone & Roberta Curini. (2013) Screening of methylenedioxyamphetamine- and piperazine-derived designer drugs in urine by LC-MS/MS using neutral loss and precursor ion scan. Journal of Mass Spectrometry 48:1, pages 49-59.
Crossref
M.D. Arbo, M.L. Bastos & H.F. Carmo. (2012) Piperazine compounds as drugs of abuse. Drug and Alcohol Dependence 122:3, pages 174-185.
Crossref
Donald G. BarcelouxBrandon Wills & Timothy Erickson. 2012. Medical Toxicology of Drug Abuse. Medical Toxicology of Drug Abuse 156 192 .
M. Perrin, Y. Lecompte, O. Roussel, R. Le Boisselier, J. Bourgine & A. Coquerel. 2012. Traité De Toxicologie Médico-judiciaire. Traité De Toxicologie Médico-judiciaire 507 547 .
Leo J. Schep, Robin J. Slaughter, Wayne A. Temple & Paul Gee. (2011) Comments on BZP and New Zealand's alternative approach to prohibition. Drug Testing and Analysis 4:1, pages 57-57.
Crossref
. (2011) Response to the letter: Comments on BZP and New Zealand's alternative approach to prohibition. Drug Testing and Analysis 4:1, pages 58-58.
Crossref
T. Bassindale. (2011) Benzylpiperazine: the New Zealand legal perspective. Drug Testing and Analysis 3:7-8, pages 428-429.
Crossref
Simon Elliott. (2011) Current awareness of piperazines: pharmacology and toxicology. Drug Testing and Analysis 3:7-8, pages 430-438.
Crossref
Christine Watson & Jonathan Wilkinson. (2011) The intensive care management of common and uncommon drugs of misuse. British Journal of Hospital Medicine 72:4, pages 211-218.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.